MME advised Reata Pharmaceuticals in connection with the closing of the secured term loan financing for up to USD 275 million from funds managed by Pharmakon Advisors, LP.
Reata Pharmaceuticals, Inc. (Nasdaq: RETA), is a global pharmaceutical company primarily focused on investigating experimental oral antioxidative and anti-inflammatory drugs. Pharmakon Advisors, LP, is a leading investor in non-dilutive debt for the life sciences industry and the investment manager of the BioPharma Credit funds.
MME team was led by Peter Kuhn (Legal Partner) and included Thomas Linder (Tax Partner), Jacqueline Brunner (Legal Associate) and Eric Sutter (Senior Tax Advisor).